CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 30 enrolled
Drug / intervention
Phosphorus Supplement +1 moredrug
Likely dose
Phosphorus Supplement 250 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02016235
NCT02016235Phase 2Completed
CompareCT.gov

Role Of Phosphorus And FGF 23 In Patients With Dent Disease

Mayo Clinic·interventional·Posted Dec 19, 2013·Updated Mar 23, 2020

In Brief

A Phase 2 clinical trial evaluating Phosphorus Supplement and Observation for Dent Disease. Completed, enrolled 30 participants across 1 site.

Detailed Summary

Patients with Dent disease have suppressed levels of FGF 23 which contributes to hypercalciuria, kidney stones, nephrocalcinosis and renal failure. Supplementation with phosphorus may reduce hypercalciuria.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDent Disease
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedDec 19, 2013
Enrollment StartSep 1, 2014
Primary CompletionJan 1, 2019
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 12.5 years ago

Interventions

Phosphorus Supplementdrug

250 mg po qid

Observationother

Baseline blood and urine measurements only